证券代码：603716 证券简称：塞力医疗 公告编号：2025-070 债券代码：113601 债券简称：塞力转债 塞力斯医疗科技集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ? 塞力斯医疗科技集团股份有限公司（以下简称"公司"）控股股东赛海 （上海）健康科技有限公司（以下简称"赛海科技"）持有公司 21,642,540 股 无限售条件流通股股票，占公司总股本的 11.33%（截至 2025 年 6 月 30 日总股 本，下同）。赛海科技累计质押公司股份 14,000,000 股，占其持有公司股份比 例为 64.69%，占公司总股本比例为 7.33%。 ? 公司实际控制人温伟先生持有公司股份 9,634,208 股，占公司总股本比 例为 5.04%。近日，温伟先生将其中 3,000,000 股股份办理完成了解除质押登记 手续，本次解除质押手续办理完毕后，温伟先生累计质押公司股份 5,300,000 股，占其持有公司股份比例为 55.01%，占公司总股本比例为 2.77%。 股东名称 温伟 本 ...

Core Points - The company will pay interest on its convertible bonds on August 21, 2025, for the period from August 21, 2024, to August 20, 2025 [1][2] - The total amount of the convertible bonds issued is 543.31 million yuan, with a face value of 100 yuan per bond [1][4] - The coupon rate for the fifth year is set at 2.50%, resulting in an interest payment of 2.50 yuan per bond (before tax) [2][4] Summary by Sections Bond Information - The convertible bonds are named "塞力转债" with a code of 113601, and they can be converted into A-shares of the company [1][4] - The bonds were issued on August 21, 2020, and will mature on August 20, 2026 [1][4] - The bond's initial conversion price was 16.98 yuan per share, while the latest conversion price is 12.00 yuan per share [4] Interest Payment Details - Interest will be paid annually, with the first payment occurring on August 21, 2021 [2][5] - The interest payment dates are as follows: - Record date: August 20, 2025 - Ex-dividend date: August 21, 2025 - Payment date: August 21, 2025 [2][4] Taxation Information - Individual investors are subject to a 20% tax on interest income, resulting in a net payment of 2.00 yuan per bond after tax [6][7] - Non-resident enterprises are exempt from corporate income tax on interest income until December 31, 2025 [7] Contact Information - The company is located at 1310 Jinshan Avenue, Dongxihu District, Wuhan, and can be contacted via email at ir@thalys.net.cn [7][8]

Core Viewpoint - As of August 12, 2025, the stock price of Sely Medical closed at 29.18 yuan, reflecting a decline of 3.89% from the previous trading day, with a trading volume of 1.346 billion yuan and a turnover rate of 23.82% [1] Company Overview - Sely Medical's main business encompasses both the medical commercial and industrial sectors, with the commercial segment accounting for over 97% of its revenue [1] - The company is associated with several concept sectors, including pharmaceutical commerce, Hubei region, and biological vaccines [1] Shareholder Activity - On the evening of August 12, the company announced that its actual controller, Wen Wei, has fully released the pledge on 3 million shares. Following this release, the total pledged shares held by Wen Wei decreased to 5.3 million, representing 55.01% of his total holdings [1] Capital Flow - On August 12, Sely Medical experienced a net outflow of 206 million yuan in principal funds, which accounted for 3.7% of its circulating market value. Over the past five trading days, the cumulative net outflow reached 131 million yuan, representing 2.34% of its circulating market value [1]

（编辑 姚尧） 证券日报网讯 8月12日晚间，塞力医疗发布公告称，公司于近日收到实际控制人温伟先生的通知，温伟 先生将前期质押给北京湘钢钢铁材料销售有限公司的3，000，000股股份全部办理完成了解除质押业 务。 ...

截至发稿，塞力医疗市值为56亿元。 每经头条（nbdtoutiao）——未收车就要结清20多万元尾款，否则5000元定金作废？小米汽车知情人 士：涉及两种特殊情况；律师解读→ （记者 王晓波） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经AI快讯，塞力医疗（SH 603716，收盘价：29.18元）8月12日晚间发布公告称，塞力斯医疗科技集 团股份有限公司控股股东赛海（上海）健康科技有限公司持有公司约2164万股无限售条件流通股股票， 占公司总股本的11.33%。赛海科技累计质押公司股份1400万股，占其持有公司股份比例为64.69%，占 公司总股本比例为7.33%。 公司实际控制人温伟先生持有公司股份约963万股，占公司总股本比例为5.04%。近日，温伟先生将其 中300万股股份办理完成了解除质押登记手续，本次解除质押手续办理完毕后，温伟先生累计质押公司 股份530万股，占其持有公司股份比例为55.01%，占公司总股本比例为2.77% 。截至本公告披露日，公司控股股东赛海科技及实际控制人温伟先生累计质押公司股份数为1930万股， 占其合计持有公司股份比例为61. ...

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-069 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于"塞力转债"付息公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 塞力斯医疗科技集团股份有限公司（以下简称"公司"）2020 年 8 月 21 日 公开发行的可转换公司债券（以下简称"本期债券"）将于 2025 年 8 月 21 日支 付自 2024 年 8 月 21 日至 2025 年 8 月 20 日期间的利息。根据公司《公开发行可 转换公司债券募集说明书》（以下简称"《募集说明书》"）及《公开发行可转 换公司债券上市公告书》（以下简称"《上市公告书》"）有关条款的规定，现 将有关事项公告如下： | 债券名称 | 塞力斯医疗科技集团股份有限公司可转换公司债券 | | --- | --- | | 债券简称 | 塞力转债 | | 债券代码 | 113601 | | 债券类型 | 可转换为 ...

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-070 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于实际控制人部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 塞力斯医疗科技集团股份有限公司（以下简称"公司"）控股股东赛海 （上海）健康科技有限公司（以下简称"赛海科技"）持有公司 21,642,540 股 无限售条件流通股股票，占公司总股本的 11.33%（截至 2025 年 6 月 30 日总股 本，下同）。赛海科技累计质押公司股份 14,000,000 股，占其持有公司股份比 例为 64.69%，占公司总股本比例为 7.33%。 公司实际控制人温伟先生持有公司股份 9,634,208 股，占公司总股本比 例为 5.04%。近日，温伟先生将其中 3,000,000 股股份办理完成了解除质押登记 手续，本次解除质押手续办理完毕后，温伟先生累计质押公司股份 5,300,000 股，占其 ...

证券之星消息，8月12日医药商业板块较上一交易日下跌0.28%，塞力医疗领跌。当日上证指数报收于 3665.92，上涨0.5%。深证成指报收于11351.63，上涨0.53%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301015 | 百洋医药 | 26.39 | 4.31% | 13.85万 | | 3.60亿 | | 301408 | 华人健康 | 15.38 | 0.72% | 19.09万 | | 2.94亿 | | 002788 | 醫症医药 | 8.76 | 0.46% | 7.10万 | | 6226.18万 | | 000078 | 海王生物 | 2.73 | 0.37% | 54.67万 | | 1.51亿 | | 603368 | 柳药集团 | 18.35 | 0.22% | 8.06万 | | 1.48亿 | | 600713 | 南京医药 | 5.27 | 0.19% | 10.26万 | | 5411.55万 | | ...

Group 1 - The SPD concept is gaining traction in the secondary market, with companies like Seli Medical, Guoke Hengtai, and Chongyao Holdings seeing significant stock price increases [1] - SPD stands for Supply, Processing, and Distribution, representing a modern supply chain management model in healthcare [1] - SPD business involves operators signing contracts with medical institutions to centralize the supply, inventory, processing, and distribution of medical materials [1] Group 2 - The SPD model allows companies to build smart supply chain management platforms for medical institutions, providing diversified services to enhance operational efficiency [1] - The introduction of lean management in SPD can reduce waste, optimize processes, and lower procurement costs for medical institutions [1] - The analyst predicts a substantial market demand for SPD in Chinese hospitals due to the rising costs of medical supplies, which account for 50% to 55% of hospital expenses [2] Group 3 - Companies are actively responding to the growing interest in SPD and hospital information technology on investor platforms [2] - Seli Medical claims a significant market share in SPD projects and aims to expand through regional cooperation [2] - Chongyao Holdings has implemented around 80 SPD projects across 14 provinces, serving nearly 70 medical institutions [2]

Company Overview - As of August 8, 2025, the stock price of Sely Medical is reported at 27.60 yuan, reflecting an increase of 0.73% from the previous trading day [1] - The company operates in the pharmaceutical commercial sector, focusing on medical testing centralized services and the research, production, and sales of in vitro diagnostic products [1] - Sely Medical's product range includes biochemistry, immunology, and molecular diagnostics, with business operations extending across multiple regions, including Hubei [1] Stock Performance - During the trading session on August 8, Sely Medical's stock exhibited significant volatility, with a morning rebound at 9:35 AM leading to a rise of over 2% within five minutes, followed by a quick pullback at 9:44 AM with a drop exceeding 2% [1] - The stock's opening price was 27.11 yuan, reaching a high of 28.40 yuan and a low of 26.20 yuan, resulting in a trading range of 8.03% [1] - The total trading volume for the day amounted to 9.85 billion yuan [1] Capital Flow - On August 8, the net inflow of main funds was 33.17 million yuan, accounting for 0.63% of the circulating market value [1] - However, over the past five trading days, the overall trend for main funds has shown a net outflow of 456 million yuan, which represents 8.65% of the circulating market value [1]